Listen to this article
What are NENs?
Neuroendocrine neoplasms (NENs) are cancers that start in hormone‑producing (neuroendocrine) cells: there are 2 key classifications based on differentiation (how cells look and behave):
- Neuroendocrine Tumours are well-differentiated with a slow to moderate growth rate
- Neuroendocrine Carcinomas are poorly-differentiated with a rapid growth rate.
They are biologically different from each other – and from more common cancers such as:
- Pancreatic adenocarcinoma (PDAC)
- Bowel cancer
- Lung cancer
This difference is important because it means: NET, NEC & PDAC need different treatments, based on their biology
What is Daraxonrasib?
Daraxonrasib (RMC‑6236) is a new targeted cancer drug taken as a tablet.
- It is not chemotherapy
- It is designed to block a cancer growth signal called RAS/KRAS
How it works
Some cancers have a “growth switch” stuck in the ON position (RAS/KRAS).
Daraxonrasib works by:
- Blocking that stuck signal
- Slowing or stopping cancer growth
Think of it like:
A car with the accelerator stuck down — this drug tries to cut the fuel line to the accelerator
Who is this drug for?
The major clinical trial (NEJM, 2026) studied people with:
- Metastatic pancreatic adenocarcinoma (PDAC)
- Cancer that had already been treated with chemotherapy
- Tumours driven by KRAS mutations (present in >90% of these cancers)
What benefit was seen?
- Survival increased:
- ~13.2 months vs ~6.7 months
- Cancer control improved
- Side effects were often more manageable than chemotherapy
Important: This is not a cure — but it is a major step forward
Does this apply to neuroendocrine cancers?
No — not for those with NET
Unknown as yet – for those with NEC
Why not?
- Different tumour type
This drug was tested in Pancreatic adenocarcinoma (PDAC)
NENs (both NET & NEC) are different types of cancer
- Different genetic “drivers”
- Pancreatic adenocarcinoma: KRAS mutations in >90%
- NENs are usually driven by different genes, such as:
- MEN1
- DAXX / ATRX
- mTOR pathway genes
KRAS mutations are:
- Rare in most NENs
- But MAY sometimes be seen in more aggressive tumours (NECs)
- Trial exclusion
- Neuroendocrine tumours were not included in the study
- Evidence currently applies to RAS‑driven cancers only
What this means in practice
- Likely relevant: Pancreatic adenocarcinoma with KRAS mutation
- Not currently relevant: NET or NEC
- Possible future use:
- Rare cases where a NEC has a confirmed RAS mutation
- Likely via clinical trials
What is genomic (molecular) testing?
Genomic testing (tumour profiling) looks at the DNA inside your tumour.
It helps to:
- Identify what is driving the cancer
- Match you to the right treatment
- Find clinical trial options
This is different from inherited genetic testing as it looks at the tumour, not what you were born with
Why genomic testing matters in cancer care including NENs
Not all cancers are the same – and not all neuroendocrine cancers are the same
They behave differently depending on their molecular “engine”
What testing can help with
- Confirming tumour type – in this instance the difference between PDAC, pNET & pNEC e.g.:
- NET (well‑differentiated)
- NEC (more aggressive)
- Guiding treatment
| Finding | What it might mean |
| mTOR pathway changes | May respond to targeted drugs (e.g. Everolimus) |
| Somatostatin receptors (SSTR) | Enables scans and PRRT therapy |
| MEN1 / DAXX / ATRX | Helps understand prognosis |
| High mutation burden (rare) | May allow immunotherapy |
- Identifying trial options
- Including access to:
- New targeted drugs
- Treatments not yet widely available
When is genomic testing most useful? You may be offered testing if you have:
- Advanced or metastatic disease
- Faster‑growing or higher‑grade tumours
- Limited treatment options
- Unclear diagnosis
- Interest in clinical trials
How are NENs usually treated?
Treatment depends on tumour type and biology, and may include:
- Surgery [NET – stage 1 NEC]
- Somatostatin analogues [NET]
- PRRT (radioligand therapy) [NET]
- Targeted therapies (e.g. Everolimus) [NET/NEC]
- Chemotherapy (in selected cases) [NEC – some NET]
- Interventional radiology / endoscopy [NET/NEC]
- Clinical trials [NET/NEC]
Why is personalised treatment important? The key principle:
The right treatment only works if it matches your tumour’s biology
Where does Daraxonrasib fit?
- Designed for cancers with RAS/KRAS mutations
- Effective in pancreatic adenocarcinoma (PDAC)
- Not currently a treatment for most neuroendocrine cancers
Exception:
- Rare aggressive NECs with KRAS mutations
- May be considered for future trials
Questions you can ask / discuss with your care team
- “What treatment best fits my tumour type?”
- “Is it NET or NEC?”
- “Has my tumour had genomic testing?”
- “What is driving my tumour?”
- “Are there any targetable mutations?”
- “Am I eligible for a clinical trial?”
Key points:
- NETs and NECs are biologically different cancers – and both are different to PDAC
- This kind of treatment depends on your tumour’s genetic profile
- KRAS‑targeted drugs (like Daraxonrasib) are not for most neuroendocrine cancers
- Genomic testing can help guide personalised treatment decisions
Essentially it’s about finding and using the right drug → right tumour → right patient
References – please note – not all are Open Access – but abstract available.
Killock, D.(2026) Nat Rev Clin Oncol Pan-RAS inhibitor Daraxonrasib shows promise in pancreatic cancer.
O’Reilly et al (2026) N Engl J Med Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
Wolpin et al (2026) N Engl J Med abstract 2026;394:1790-1802: Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer